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glycemia and at preventing/reducing tissue damage, including cardiovascular (CV) events. For
approval, novel diabetes drugs undergo early systematic investigation to assess CV safety. This
review provides an updated analysis of the results of recent studies examining novel diabetes
medications and CV outcomes.
Data synthesis: The new regulatory guidelines enforce adjudication of all CV events when testing
novel diabetes drugs. Endpoints of CV mortality, myocardial infarction (MI), stroke and hospital-
ization for heart failure (HF) were included in the most recent clinical studies on novel antihy-
perglycemics. These are: the incretin mimetics glucagon-like peptide 1 (GLP-1) receptor
agonists (GLP1-RA), the incretin enhancers dipeptidylpeptidase-4 (DPP-4) inhibitors (DPP4-I or
gliptins), and the sodium-glucose cotransporter (SGLT2) inhibitors (SGLT2-I or gliﬂozins). The
studies ELIXA and EXAMINE, testing lixisenatide and alogliptin, respectively, revealed non-
inferiority versus placebo in terms of CV safety. The SAVOR-TIMI 53 results conﬁrmed overall
CV safety of saxagliptin, but raised a warning related to the increase in the risk of hospitalization
for HF in the saxagliptin group. Recently, TECOS revealed a particularly favorable CV proﬁle for
sitagliptin while EMPA-REG showed a signiﬁcant CV risk reduction in empagliﬂozin treated sub-
jects. Ongoing studies will provide additional data on CV safety for other GLP1-RAs, DPP4-I and
SGLT2-I.
Conclusions: Results of safety outcome studies focused on CV events, including HF and mortality
for CV causes, are not homogeneous. A critical analysis of these studies may help cardiologists
and diabetes specialists to adapt their therapeutic choices to individual patients.
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Type 2 diabetes affects approximately 400 million
people worldwide [1], while mortality accounts for about
4.9 million deaths/year. The risk of developing CV
disease is two-fold higher in diabetic patients than in
non-diabetic individuals [2]. CV disease represents the
cause of death in 60% of patients with diabetes and a
great proportion of them develop serious CV-relatedof Atherosclerosis, the Italian Society of Human Nutrition, and the Department of
an open access article under the CC BY-NC-ND license (http://creativecommons.
760 R.C. Bonadonna et al.complications. In particular, the incidence rates of
congestive heart failure (HF) in individuals with diabetes
are 5-fold (in women) and 2.4-fold (in men) higher
than the general population [3]. Diabetes treatments
aim at preventing the detrimental metabolic effects
of high glucose levels as well as the development
of microvascular and macrovascular damage and the
consequent complications.
Levels of glycated hemoglobin (HbA1c) have been
largely used as a marker for glycemic control in type 2
diabetes, and reduction in HbA1c is used to monitor the
efﬁcacy of diabetes treatments. In the 10-year observa-
tional post-trial monitoring of the United Kingdom Pro-
spective Diabetes Study (UKPDS), improved glycemic
control as reﬂected by HbA1C reduction was associated
with a reduction in the long-term risk of CV complications
[4]. However, a clear direct relationship between HbA1c
reduction and improvement in CV risk has not been un-
equivocally demonstrated so far, while data have emerged
suggesting that some of the agents used to treat diabetes
might increase CV risk [5]. In particular, controversial ev-
idence emerged by studies on rosiglitazone. While the
ADOPT study group reported that patients treated with
rosiglitazone or metformin developed CV events in similar
proportions [6], a subsequent meta-analysis of 42 qualiﬁed
studies hinted that rosiglitazone was associated with a
signiﬁcant increase of MI risk and with a tendency to
increased CV death risk [7]. Different results emerged from
the RECORD study, conducted in 4447 patients with type 2
diabetes treated with rosiglitazone or standard glucose-
lowering drugs. Although an increased risk of HF was
conﬁrmed in patients treated with rosiglitazone compared
to standard antidiabetes treatments, external reevaluation
of RECORD was not conclusive for a possible increased risk
of MI (H.R.: 1.13; C.I.: 0.80e1.59), somehow reassuring for
MACE (H.R.: 0.95; CI: 0.78e1.17) [8], and in general close
agreement with earlier reports [9,10]. However, this con-
troversy raised concern and prompted main regulatory
agencies to introduce changes in the approval process of
new antidiabetes drugs, with particular focus on CV safety
[11,12].
A mandatory prescription of the new guidance for the
approval process of novel drugs for type 2 diabetes is that
all CV events occurring in phase II and phase III trials
must be adjudicated by an independent committee in a
blinded fashion. The event recording must include CV
mortality, MI and stroke endpoints, and it also may
include hospitalization for acute coronary syndrome
(ACS), HF and urgent revascularization procedures [11,12].
Studies are required to include patients at high CV risk
such as elderly patients, patients with relatively advanced
disease, and patients with various degrees of renal
impairment [13]. The FDA guidelines for approval of novel
diabetes drugs not only mandate collection and adjudi-
cation of major CV adverse effects (MACE, deﬁned as the
composite of CV death, MI or stroke) during phase II and
phase III registration trials, they also call for the pooled
data analysis. In this analysis, comparing MACE riskbetween exposed and non-exposed subjects, if the upper
limit of the 95% conﬁdence interval is below 1.8 and above
1.3 the drug can be approved for clinical use, however the
manufacturer company is bound to perform a formal
randomized, controlled CV safety outcome trial [11,12].
Given the relatively low CV risk of the subjects enrolled in
the typical trials for the registration of novel diabetes
drugs, the number of occurring events is generally low.
This results in wide conﬁdence intervals of the point es-
timates of the CV risk in exposed and non-exposed sub-
jects, making it almost impossible that the upper limit of
the conﬁdence interval falls below 1.3. This is the reason
why for virtually all of the novel marketed diabetes drugs
a randomized, controlled CV safety outcome trial has been
performed or is ongoing [5].
This review critically examines the results of the most
recent clinical studies on CV outcome, through the inte-
grated contribution of both cardiology and diabetology
specialists. Critically reviewing the main recent studies on
the CV safety of novel antidiabetes drugs meets a physi-
cians’ primary need: every time therapeutic and/or pre-
ventive strategies are used, the ﬁrst imperative is not to
harm patients. In other words, to abide by the oldest and
wisest rule of Medicine: primum non nocere [14].
Conventional and novel diabetes drugs
Ensuring proper glucose control delays the development
of microvascular complications and eventually helps in
mitigating CV risk in type 2 diabetes [15,16]. Achieving and
maintaining optimal glucose control without incurring in
treatment adverse effects such as weight gain and hypo-
glycemia is a challenging task, particularly when tradi-
tional diabetes drugs are used. Thus, in the attempt to
make diabetes treatment easier and safer, new therapeutic
options based on novel molecular mechanisms were
developed.
Among these, two classes of drugs introduced for
treatment of diabetes in the course of the last 10 years
base their therapeutic effects on the incretin axis. Upon
eating, the secretion of multiple gastrointestinal hormones
(incretins) is instrumental - by several mechanisms - in
handling ingested carbohydrate/glucose. Among these
hormones, glucagon-like peptide 1 (GLP-1), identiﬁed by
cloning the pro-glucagon gene, was shown to promote
insulin and to inhibit glucagon secretion.
Two therapeutic approaches were developed to take
advantage of GLP-1 incretin activity: 1) stable GLP-1 re-
ceptor agonists (incretin mimetics), and 2) inhibitors of
dipeptidylpeptidase-4 (DPP-4), the enzyme responsible for
GLP-1 degradation (incretin enhancers).
The incretin mimetics are agonists of the GLP-1 recep-
tor having a molecular structure impervious to DPP4
mediated degradation. Therefore, their half-life varies from
a few hours to several days after subcutaneous adminis-
tration. Their use leads to improved glycemic control,
signiﬁcant weight loss and low risk of hypoglycemia [17].
Several GLP-1 receptor agonists have been developed, with
Novel antidiabetic drugs and cardiovascular risk 761different pharmacokinetics and pharmacodynamics. Those
currently approved for use in diabetes are exenatide, lix-
isenatide, liraglutide, albiglutide and dulaglutide [18].
DPP-4 inhibitors lead to an improved glycemic control
by prolonging endogenous GLP-1 half-life. Their use en-
tails a minimal hypoglycemia risk and it is not associated
with weight gain. Moreover, DPP-4 inhibitors, as well as
incretin mimetics, might have a positive effect on b-cell
preservation through stimulation of cell proliferation
and inhibition of apoptosis, although this has yet to be
conﬁrmed in humans [19].
Many oral DPP-4 inhibitors have been developed with
speciﬁc and potent inhibitory activity. Among these,
alogliptin, linagliptin, sitagliptin, saxagliptin and vilda-
gliptin have undergone thorough investigation in preclin-
ical and clinical studies [20].
Another novel therapeutic approach is based on pro-
moting urinary glucose loss by hampering renal tubular
reabsorption of ﬁltered glucose. Kidney glucose reab-
sorption is mediated in part by the sodiumeglucose
cotransporter 2 (SGLT2), which seems to be overexpressed
and hyperactive in diabetes experimental models and in
type 2 diabetes patients [21e23]. The recently developed
SGLT2 inhibitors block the transporter, inhibit glucose
reabsorption and enhance glucose loss in the urine,
thereby lowering plasma glucose proportionately to
glucose concentration by an insulin-independent mecha-
nism. The drugs of this new class are independent of
pancreatic function and/or of insulin resistance and their
use is associated with improved glycemic control, signiﬁ-
cant weight loss, low risk of hypoglycemia and improved
blood pressure [21,24]. SGLT2 inhibitors empagliﬂozin,
canagliﬂozin and dapagliﬂozin are available as mono-
therapy or in combination with conventional antidiabetes
agents.
Clinical studies: completed and ongoing trials
The overall design of most of the CV outcome safety trials
conducted with the novel diabetes drugs calls for use of
the drug to be tested as add on to patient standard dia-
betes treatment. The latter needs to be adjusted so that the
best possible glucose control according to local standards
is achieved in both the active drug and the placebo groups.
This approach, which aims at glucose equipoise, minimizes
the potential confounding effect of different level of gly-
cemic control eventually achieved in the study groups and
allows evaluation of the effects on CV outcomes of the
study drug per se, independently of overall metabolic
improvement.
To date, the following CV outcome studies with incretin
agonists, DPP-4 inhibitors and SGLT2 inhibitors have been
completed and published (Table 1).
Incretin agonists
Lixisenatide: The ELIXA study (ClinicalTrials.gov id.
NCT01147250) evaluated lixisenatide effects on CV out-
comes in patients with type 2 diabetes who hadexperienced a recent ACS. Centers located in 49 countries
recruited more than 6.000 patients with type 2 diabetes
and recent ACS, with a median follow-up of 25 months.
Beside the positive effects of lixisenatide on glycemic
control and weight loss, no differences were observed for
the primary endpoint (MACE), including hospitalization
for HF and deaths from CV causes, between lixisenatide
and placebo groups [25].
DDP-4 inhibitors
Saxagliptin. SAVOR-TIMI 53 (ClinicalTrials.gov id.
NCT01107886) assessed safety and efﬁcacy of saxagliptin
on CV outcomes in patients with type 2 diabetes at risk
for CV events. The study was conducted in 788 institutions
in 26 countries for a total of 16 492 patients followed
for up to 2.9 years. The primary endpoint of MACE
occurred with a statistical signiﬁcance of P  0.001 for
non-inferiority of saxagliptin versus placebo. Unexpect-
edly, saxagliptin treatment was associated with a signiﬁ-
cant 27% increase in hospitalization for HF, as compared to
placebo (P Z 0.007) [26].
Alogliptin. The multicenter non-inferiority EXAMINE
study (ClinicalTrials.gov id. NCT00968708) was carried out
in approximately 5400 patients with type 2 diabetes and
ACS, who were followed up to 40 months to deﬁne the CV
safety proﬁle of alogliptin. For the primary CV endpoint
(MACE) no statistically signiﬁcant differences were
observedbetweengroups treatedwithalogliptinorplacebo.
Similarly, there was no difference in total CV deaths [27].
Hospital admission forHF in theEXAMINE trialwas assessed
through a further subgroup analysis, showing a numerical,
albeit statistically not signiﬁcant, increase of hospitalization
forHFor anyaggravationof existingHFoutcomes inpatients
with recent ACS treated with alogliptin [28].
On the basis of these results, FDA has very recently
announced that type 2 diabetes drugs containing sax-
agliptin and alogliptin will have a new warning cautioning
about a potential increased risk for heart failure associated
with the use of these drugs, particularly in patients with
heart or kidney disease (http://www.fda.gov/Safety/
MedWatch/SafetyInformation).
Sitagliptin. Two pooled post-hoc analyses in approxi-
mately 25 000 patients with type 2 diabetes treated with
sitagliptin or with other agents revealed that the sita-
gliptin treatment was associated with no increased MACE
risk [29,30]. The large TECOS study (ClinicalTrials.gov id.
NCT00790205) assessed long-term CV safety of sitagliptin
added to usual care, with a median follow-up of 3 years in
14 671 randomized patients with type 2 diabetes and
established CV disease. Incidences of MACE and of hospi-
talization for HF were superimposable in sitagliptin and
placebo treated arms. According to this safe proﬁle, no
differences versus placebo in the rate of the composite
outcome of hospitalization for HF and CV death were
consistently observed [31]. Thus for sitagliptin, as opposed
to saxagliptin and alogliptin, no signal was detected for
increased risk of heart failure and no label warning has
been mandated. Recent results, presented at the Diabetes
Table 1 Summary of CV outcome studies with novel diabetes drugs in patients with type 2 diabetes.
ELIXA SAVOR-TIMI 53 EXAMINE TECOS EMPA-REG
Reference Pfeffer et al., 2015 Scirica et al., 2013 White et al.,. 2013;
Zannad et al., 2015
Green et al., 2015 Zinman et al., 2015
Participants(n) 6068 16 492 5380 14 671 7020
Intervention lixisenatide
10 mg daily, up to
20 mg daily after
2 weeks
saxagliptin
2.5 mg or 5mg daily,
according to GFR
alogliptin
6.5,12.5 or 25 mg
daily, according to
GFR
sitagliptin
50 mg or100 mg
daily, according to
GFR
empagliﬂozin
10 mg or 25 mg
daily
Inclusion criteria ACSb within 180
days
established CV
diseasec
multiple risk factor
for vascular disease
d
ACS b within
previous 15e90
days
established CV
disease c
established CV
diseaseh
Exclusion criteria
(of CV interest)
- age less than 30
years
- coronary inter-
vention within 90
days
- age less than 40
years
- incretin therapy
in previous 6
months
- end-stage renal
disease
- diagnosis of type
1 diabetes
- unstable cardiac
disorders e
- age less than 50
years
- incretin or thia-
zolidinedione
therapy in previ-
ous 3 months
- GFR< 30
- age less than 18
years
- ACS, stroke or TIA
within 2 months
- no glucose-
lowering therapy
in previous 3
months
- GFR< 30
Median follow-up
(years)
2.1 2.1 1.5 3.0 3.1
CV outcomea nZ 406 (13.4%)
HR 1.02 (0.89e1.17)
P < 0.001
nZ 613 (7.3%)
HR 1.00 (0.89e1.12)
P Z 0.001
nZ 305 (11.3%)
HR 0.96 (1.16) f
P < 0.001
n Z 839 (11.4%)
HR Z 0.98 (0.88
e1.09)
P < 0.001
n Z 490 (10.5%)
HR 0.86 (0.74e0.99)
P < 0.001
Hospitalization
for HF
nZ 122 (4%)
HR 0.96 (0.75e1.23)
P Z 0.75
nZ 289 (3.5%)
HR Z 1.27 (1.07
e1.51)
P Z 0.007
nZ 106 (3.9%)
HR 1.19 (0.90e1.58)
P Z 0.220
n Z 228 (3.1%)
HR Z 1.00, 95% CI;
0.83e1.20
P Z 0.98
n Z 126 (2.7%)
HR 0.65 (0.50e0.85)
P Z 0.002
Deaths nZ 211 (7%)
HR 0.94 (0.78e1.13)
P Z 0.50
nZ 420 (4.9%)
HR 1.11 (0.96e1.27)
P Z 0.15
nZ 112 (4.1%)
HR 0.88 (0.71e1.09)
P Z 0.23g
n Z 547 (7.5%)
HR 1.01 (0.90e1.14)
P Z 0.88
n Z 269 (5.7%)
HR 0.68 (0.57e0.82)
P < 0.001
Abbreviations. ACS Z acute coronary syndrome; GFR Z glomerular ﬁltration rate (ml/min/1.732 body-surface area); TIA Z transient ischemic
attack.
P values are calculated for non-inferiority to placebo or other hypoglycemic drugs, except as described in (6); hazard ratio values are calculated
with 95% CI.
a MACE: composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke.
b Acute myocardial infarction, unstable angina requiring hospitalization.
c Deﬁned as: history of major coronary artery disease, ischemic cerebrovascular disease, atherosclerotic peripheral arterial disease.
d At least one of: dislipidemia, hypertension, or active smoking.
e New York Heart Association class IV HF, refractory angina, uncontrolled arythmias, critical valvular heart disease, severe uncontrolled
hypertension.
f Upper boundary of the one-sided repeated 95% CI, alpha level Z 0.01.
g P value for testing superiority of alogliptin to placebo.
h Deﬁned as: history of myocardial infarction, history of stroke, single- and multi-vessel coronary artery disease, unstable angina, occlusive
peripheral artery disease.
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conﬁrmed that sitagliptin did not increase the MACE risk
also in a subgroup of 2004 elderly patients (aged 75 years
or older) with established CV disease [32].
SGLT2 inhibitors
Empagliﬂozin: The randomized EMPA-REG study (Clin-
icalTrials.gov id. NCT01131676) examined the effect of
empagliﬂozin on CV morbidity and mortality in patients
with type 2 diabetes at high risk for CV events. More than
7000 patients (median follow-up 3.1 years) with estab-
lished CV disease were treated at 590 sites in 42 countries.Patients treated with empagliﬂozin had signiﬁcantly lower
incidence rate of the primary end point (MACE). Notably,
patients treated with empagliﬂozin (at both doses of
10 mg or 25 mg) also had reduced cumulative rates of
hospitalization for HF (2.7% vs 4.1%; P Z 0.002) and of
death from CV causes (3.7%, vs. 5.9%; P < 0.001) compared
with the placebo group [33].
A systematic review and meta-analysis, including 6 reg-
ulatory submissions (37 525 patients) and 57 published
studies (33 385 patients), assessed the effects on CV events
and the safety outcomesof seven SGLT2 inhibitors. Data from
this analysis conﬁrmed the ﬁndings of EMPA-REG study for
empagliﬂozin and indicated that no clearly different safety
Novel antidiabetic drugs and cardiovascular risk 763outcomesmay result fromotherdrugs across the class. These
ﬁndingswill be validated by the ongoing long-termCVsafety
studies for SGLT2 inhibitors [34].
Ongoing studies
The trials described above have been completed and their
results have been published. However, several other CV
outcome safety studies are presently being performed to
assess the cardiovascular safety of novel diabetes drugs. As
to drugs already approved for clinical use, current ongoing
studies are investigating CV safety of incretin mimetics
(albiglutide, dulaglutide, exenatide and liraglutide), DPP-4
inhibitors (linagliptin and vidagliptin) and SGLT2 in-
hibitors (canagliﬂozin and dapagliﬂozin).
Incretin agonists ongoing studies
Albiglutide. The HARMONY Outcomes study (Clinical-
Trials.gov id. NCT02465515) aims at testing whether albi-
glutide, a recombinant long-acting, peptidase-resistant
GLP-1R agonist resulting from the fusion of a GLP-1
dimer with human albumin [35], affects MACE occur-
rence in patients with type 2 diabetes, alone or in com-
bination with other diabetes treatments. This Phase IV
study will be completed in May 2019.
Dulaglutide. Long-acting, once-weekly receptor agonist
dulaglutide consists of two minimally modiﬁed GLP-1 pep-
tidechain linkedbyanaminoacid linker to theFc fragmentof
human IgG4, thus protecting from the molecule from
peptidase activity and prolonging its half-life due to a size
dependent decrease in clearance [36]. The REWIND study
(ClinicalTrials.gov id. NCT01394952) is designed to assess
the possible reduction of MACE and other serious outcomes
inpatientswith type2diabeteswithprior CVdisease orwith
at least 2 CV risk factors, and under other anti-diabetes
regimen. The completion date of this study is April 2019.
Exenatide. The EXSCEL placebo-controlled multinational
study (ClinicalTrials.gov id. NCT01144338) evaluates the
effect of a once-weekly formulation of the GLP-1 mimetic
exenatide on MACE, when administered as add-on to usual
care. The study is conducted in 35 countries, aiming to
enroll 14 000 patients with type 2 diabetes and a broad
range of CV risk, over approximately 5 years until the
completion date of April 2018 [37].
Liraglutide. To assess long-term CV outcomes with the
GLP-1 analog liraglutide compared to placebo, the multi-
center randomized LEADER study (ClinicalTrials.gov id.
NCT01179048) was initiated in 2010, enrolling 9340 sub-
jects with type 2 diabetes and high CV risk [38]. The
LEADER database lock occurred on February 2015. As of
March 2016, the LEADER study sponsor announced, in
compliance with international ﬁnancial laws, that the
analysis of data had shown achievement of the primary
endpoint, with a statistically signiﬁcant reduction in CV
risk in patients treated with liraglutide versus placebo. The
study results will be presented in details at the 76th Sci-
entiﬁc Sessions of the American Diabetes Association in
New Orleans, LA, June 10e14, 2016.DDP-4 inhibitors ongoing studies
Linagliptin.The CAROLINA study (ClinicalTrials.gov id.
NCT01243424) is designed to investigate the long-term
CV impact of linagliptin versus glimepiride in patients
with type 2 diabetes and increased CV risk. The results will
help to assess CV safety and potential CV protection of
linagliptin on a background of therapy with metformin,
and to assist the decision-making process for selecting
a second glucose-lowering agent after metformin [39].
The CARMELINA CV outcome study (ClinicalTrials.gov id.
NCT01897532) compares CV and renal safety of linagliptin
versus placebo in approximately 8300 patients with type 2
diabetes and high CV risk, deﬁned by previous macro-
vascular disease and/or impaired renal function. The study
was initiated in 2013 and results are expected January
2018 [40].
Vildagliptin. The VIVIDD study (ClinicalTrials.gov id.
NCT00894868) aims at evaluating the effect of a 52-week
treatment with vildagliptin on left ventricular function in a
small cohort of 254 subjects with type 2 diabetes and
congestive HF [41]. Although this study is of short dura-
tion, not focused on hard CV end points and still ongoing,
preliminary results presented at the American Diabetes
Association showed a statistically signiﬁcant increase in
left ventricular end-diastolic volume (P Z 0.007), stroke
volume (P Z 0.002), and a trend toward an increase in
left ventricular end-systolic volume in the vildagliptin
arm. Moreover, higher, albeit not statistically signiﬁcant,
numbers of death for any cause (11 vs 4), of CV deaths
(7 vs 4) and of HF (13 vs 10) were found in the treatment
arm versus placebo [42].
SGLT2 inhibitors ongoing studies
Canagliﬂozin.Two large long-term clinical outcome
studies, CANVAS (ClinicalTrials.gov id. NCT01032629) and
CANVAS-R (ClinicalTrials.gov id. NCT01989754), the latter
being also focused on renal end points, are designed to
assess the impact of canagliﬂozin on classical CV endpoints
in patients with type 2 diabetes. The results of these
studies are expected in 2017 [43].
Dapagliﬂozin. DECLARE-TIMI58 (ClinicalTrials.gov id.
NCT01730534) is a Phase III multicenter study designed to
evaluate the effect of dapagliﬂozin in reducing MACE and
CV-related death, compared with placebo. The study esti-
mates to enroll more than 17 000 subjects with type 2
diabetes and high CV risk. DECLARE-TIMI58 is expected to
be completed in April 2019.
Conclusions and discussion
When treating diabetes most of the effort is focused on
preventing the occurrence of vascular complications or on
delaying their development. Therefore, diabetes drugs,
whose efﬁcacy is measured by the ability to reduce HbA1c,
which entails a favorable effect on microangiopathy-
driven tissue damage, also must have no adverse impact
on macroangiopathy-driven CV risk. Following the sorely
764 R.C. Bonadonna et al.debated issue of the potential association between rosi-
glitazone treatment and increased CV risk, the major reg-
ulatory agencies issued very strict guidelines mandating
detailed rules to be followed and ambitious safety goals to
be achieved for new diabetes drugs to gain deﬁnitive
admission to clinical use. Thus, for virtually all novel dia-
betes medications CV outcome safety trials have been
performed or are ongoing. Given their purpose, the
experimental design of and the characteristics of patients
recruited in these trials share some common features.
They are: 1) in most of the studies the study drug and the
comparator (in most instances placebo) are administered
on top of ongoing diabetes treatment. 2) Ongoing diabetes
treatment is titrated to aim at comparable glucose control
in both the active drug and the comparator arms. 3) Pa-
tients enrolled are at high or very high CV risk (in most
instances all or a signiﬁcant proportion of them are in
secondary prevention). 4) The primary endpoint is MACE,
i.e. a composite of CV death, non-fatal MI and non-fatal
stroke. 5) Hospitalization for HF is a secondary endpoint.
6) Studies are powered to demonstrate non inferiority
versus placebo and not to prove superiority (i.e. a protec-
tive CV effect of the study drug), although in most studies
it is pre-planned that, if the non-inferiority goal is met, the
statistical analysis for superiority of the active drug is to be
performed. It was therefore expected that these studies,
designed and powered to prove cardiovascular safety,
would be highly unlikely to show any CV beneﬁt of the
active drugs.
On the other hand, taking together the studies whose
ﬁnal results are already available, a very reassuring proﬁle
emerges for most of the drugs tested so far regarding
cardiovascular safety. However, a closer look at these re-
sults reveals a signal of increased hospitalization for HF in
patients exposed to saxagliptin, with a similar trend, albeit
not statistically signiﬁcant, also in the patients exposed to
alogliptin in the EXAMINE study. On the other hand, sita-
gliptin in the recently completed long-term TECOS study,
conducted in a very large population with type 2 diabetes
and established CV disease, showed no trend of increased
risk for MACE, HF hospitalization or other adverse CV
events. The results are particularly relevant because the
trial was powered to abide by the most stringent FDA
requirement of achieving an upper limit of the primary end
point HR conﬁdence interval lower than 1.3 [31], indicating
that patients with type 2 diabetes at high CV risk, including
HF, may beneﬁt from the glucose lowering action of sita-
gliptin, with no increase in CV complication rates. This
becomes of utmost importance when treating patients of
advanced age and/or patients with several comorbidities,
including renal failure, or concomitant risk conditions [15].
As already noted, treatment with DPP-4 inhibitors, and
the more so with sitagliptin, appears to be safe in terms of
CV events in patient populations at high CV risk: if such a
treatment is safe in these patients, it should be at least as
safe in a population at lower CV risk. However, treatment
with DPP-4 inhibitors (as well as treatment with the
incretin mimetic lixisenatide) fell short of demonstrating aCV beneﬁt, as predictable, given the above mentioned
considerations regarding the study designs.
On the other hand, treatment with the SGLT2-inhibitor
empagliﬂozin not only was proven safe in a population of
type 2 diabetic patients at high CV risk, but was also
shown to reduce CV risk. As a matter of fact, in the EMPA-
REG study a small but signiﬁcant improvement in the
composite primary outcome was observed in the active
drug group. Moreover, impressive reductions in the rates
of CV death and all cause death, as well as of hospitaliza-
tion for HF, were documented in the same group. The
mechanisms underlying these results are far from being
convincingly explained. Glucose control might hardly play
a role. Since the CV beneﬁt appeared very early after
randomization, the improvement in vascular tone regula-
tion and/or the empagliﬂozin driven natriuretic effect
might play a plausible role in risk reduction, even if these
effects can hardly account for the whole response.
Furthermore, while safety in high risk conditions is
readily extendable to lower risk conditions, beneﬁts
mostly deriving from reductions in CV death and HF hos-
pitalization rates in high risk patients - such as those
recruited in the EMPA-REG Outcome trial - might not
necessarily translate in quantitatively similar beneﬁcial
effects in a population with less advanced CV disease.
Therefore, the two questions whether EMPA-REG Outcome
proven beneﬁts are extendable to patients with shorter
duration of disease and with no clinically evident CV dis-
ease and/or whether similar results can be obtained with
other SGLT2 inhibitors still await deﬁnitive answers [44].
Moreover, the choice of the most suitable diabetes drug
for any given patient rests on considerations of efﬁcacy
and safety, but also on side effects, counter-indications,
impact on everyday life, tolerability, patient compliance
and patient preferences. Novel diabetes drugs are gener-
ally well tolerated; however, DPP-4 inhibitors have the
greatest tolerability. This is because DPP-4 inhibitors, as
SGLT-2 inhibitors, are oral drugs that can be assumed once
a day without the need of titration, with no weight gain
and with a negligible hypoglycemia risk. They have
virtually no side effects (whereas a modest polyuria and a
somewhat increased risk of genital infection are associated
with the use of SGLT-2 inhibitors) [34] and can safely be
used in older patients, as well as in patients with impor-
tant comorbidities such as renal insufﬁciency.
In conclusion, based on the results of the CV outcome
safety trials and particularly on the results of the TECOS
study, DPP-4 inhibitors, and foremost sitagliptin among
them, appear to be deﬁnitely safe with regard to the CV
system. The impressive results of the EMPA-REG study,
especially if further conﬁrmed in the next future by studies
in other SGLT-2 inhibitors, do advocate the use of these
agents in high CV risk patients with no counter-indication
to their use. However, for the vast majority of diabetic
patients, only a careful individualized evaluation of clinical
characteristics and lifestyle habits can result into the best
possible treatment strategy, considering that single drug
therapy very seldom achieves and/or maintains the
Novel antidiabetic drugs and cardiovascular risk 765desired goals and that a combination or two or more
agents is most often needed.
In conceiving these therapeutic strategies, the chronic
nature of diabetes, the need of a lifelong treatment and the
paramount importance of ensuring compliance strongly
militate in favor of the best tolerated agents, which should
be preferred whenever possible. Side effects, even the least
harmful ones, may dramatically decrease compliance and
thus seriously hinder therapeutic efﬁcacy. Primum non
nocere, the most ancient medicine’s motto, still holds true
and should be the foundation on which to build any dia-
betes therapeutic strategy.
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